Approval · Notice of Compliance 30455 · 2023
DEXILANT: Notice of Compliance 30455
Issued March 31, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30455
- Date
- March 31, 2023
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) with new safety information about Severe Cutaneous Adverse Reactions (SCARs).
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DEXILANT | Not yet assigned | — |
Medicinal ingredients
- DEXLANSOPRAZOLE 30 MG per CAP
- DEXLANSOPRAZOLE 60 MG per CAP